Advisory group approves HPV vaccine

The National Technical Advisory Group on Immunization NTAGI has granted approval for the introduction of the Human papillomavirus (HPV) vaccine in the Universal Immunisation Programme. The campaign for providing HPV vaccines had suffered a setback in 2012 following controversy around its side-effects in 2012 and a strategic legal intervention before the Supreme Court seeking revocation of the licenses of Merck Sharp & Dohme (MSD) and GlaxoSmithkline (GSK), the only two suppliers of the vaccine in India. HPV vaccine can substantially reduce the risk of cervical cancer, which is the second leading cause of cancer deaths among women in India.